Sanofi India Limited

BSE: 500674 NSE: SANOFI
Sanofi India Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1956PLC009794 Incorporated 02 May 1956 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: SANOFI · BSE: 500674 Public Limited Company pharma
Data last updated
Market Cap
₹6,511 Cr
SANOFI · NSE
Share Price
₹2,831.10
+0.13% today
Revenue
₹2,013 Cr
Dec 2024 · +0.9% YoY
EBITDA
₹453 Cr
Margin 22.5%
Net Profit
₹442 Cr
Dec 2024 · -24.9% YoY
P/E (TTM)
21.0x
P/B 9.3x
ROE
47.1%
ROCE 48.0%
Debt / Equity
0.02
Interest cover 0.4x

About Sanofi India Limited

Data last updated:

Sanofi India Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Hoechst Gmbh (Holding Company). It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 May 1956 and has been in existence for over 70 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1956PLC009794. Its GSTIN is 27AAACH2736F1ZU (Maharashtra). The company holds 25 GST registrations, of which 17 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500674 and NSE: SANOFI.

The company has an authorised share capital of ₹23.5 Cr and a paid-up capital of ₹23.03 Cr. It was formerly known as Hoechst Fedco Pharma P Ltd and Hoechst Fedco Pharma Ltd. It is led by directors including Deepak Arora (Managing Director) and Mahadev Keshav Gawade (Whole-Time Director).

Its last annual general meeting (AGM) was held on 29 April 2026, and its latest financial statements are for the year ended 31 December 2025. The registered office is at Sanofi House Cts No.117 – B L&T Business Park Saki Vihar Road Powai, Mumbai, Maharashtra, India – 400072.

As per the latest standalone financials for FY 2024-25, the company reported a revenue of ₹1,837.4 Cr, a decline of 8.7% compared to the previous year. For the same year it recorded a net profit of ₹346.38 Cr (net margin 18.9%) and EBITDA of ₹464 Cr (EBITDA margin 25.3%). The net worth stands at ₹749.2 Cr (down 12.9% YoY). Total assets are valued at ₹767.5 Cr (down 12.8% YoY).

The company has about 2,191 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 2 brands: Allergy Free and Sanofi India. As per MCA filings, the company has open charges of ₹170.72 Cr and satisfied charges of ₹40.81 Cr on record. Court records list 454 cases involving the company, including 197 filed by the company and 259 filed against it; 119 cases are pending. The company has 15 deals on record (12 market trades, 3 acquisitions); the latest was in June 2026. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 365 overdue payments to 80 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sanofiindialtd.com.

Company details

CIN L24239MH1956PLC009794
Registration Number 009794
Incorporation Date 02 May 1956
ROC Mumbai
Listing Status Listed - Listed on NSE (SANOFI); Listed on BSE (500674)
Company Status Active
Date of Last AGM 29 April 2026
Date of Balance Sheet 31 December 2025
Parent Company Hoechst Gmbh (Holding Company)
Compliance Status Active Compliant

Name history

Sanofi India has undergone 4 name changes throughout its history. The current legal name is Sanofi India Limited.

Company NameStatus
Sanofi India LimitedCurrent
Hoechst Fedco Pharma P LtdPrevious
Hoechst Fedco Pharma LtdPrevious
Aventis Pharma LimitedPrevious
Hoechst- Fedco Pharma Private LimitedPrevious
Key People
Deepak Arora Managing Director Mahadev Keshav Gawade Whole-Time Director Rachid Ayari Whole-Time Director

Contact details

Sanofi India Limited's registered office is in Mumbai, Maharashtra. Its website is sanofiindialtd.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    sanofiindialtd.com
  • Social Media
  • Registered Address
    Sanofi House Cts No.117 – B L&T Business Park Saki Vihar Road Powai, Mumbai, Maharashtra, India – 400072
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Sanofi India Limited, buy the company report.

Comprehensive company report
Sanofi India Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Sanofi India operates two associated brands: Allergy Free and Sanofi India. Each brand links to its own profile.

BrandDescriptionWebsite
Allergy Free
Allergy education and management services in healthcare by Sanofi.allergyfree.co.in
Sanofi India
Manufacturer of pharmaceutical products and vaccinessanofiindialtd.com

Financials of Sanofi India Limited

FY 2024-25 filings available

Sanofi India Limited reported revenue of ₹1,837.4 Cr (down 8.7% YoY) for FY 2024-25.

Financial Highlights

Dec 2024 · Consolidated
Revenue
₹2,013 Cr
+0.9% YoY
EBITDA
₹453 Cr
-7.1% YoY
Profit After Tax
₹442 Cr
-24.9% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsDec 2024Dec 2023
Income statement
Revenue2,0131,996
Revenue growth+0.9%-
EBITDA453488
EBITDA margin+22.5%+24.4%
Profit before tax531767
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
Balance sheet
Cash flow
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
MetricsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income statement
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Profit before tax4455318468641,258677600
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Balance sheet
Cash flow
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue438472420475406536515524
Revenue growth (YoY)+7.7%-11.9%-18.5%-9.3%-12.3%---
Other income6.204.402.804.908.703.3013.902.30
Total expenses322330330368311364397404
EBITDA11514390.3010794.90172118120
EBITDA margin+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%+22.8%
Depreciation8.909.009.509.109.109.609.609.00
Interest0.300.300.600.400.400.300.400.40
Profit before tax11213883.0010294.10165122113
Tax28.8035.3021.3026.3024.6045.8030.9030.40

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsDec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue515524464511469491515521
Revenue growth (YoY)+9.7%+6.8%-10.0%-2.0%----
Other income13.902.3039.8068.1077.4081.9057.40101
EBITDA11812096.7011099.60114122153
EBITDA margin+23.0%+22.8%+20.9%+21.6%+21.2%+23.1%+23.6%+29.3%
Depreciation9.609.009.009.109.309.209.108.90
Interest0.400.400.400.300.400.300.700.30
Profit before tax122113127169167186169244
Tax30.9030.4023.9032.5029.6034.0046.3053.90
Net profit91.3082.20103137138152123190
EPS (₹)39.6435.6944.8159.3159.7965.9553.370.00
ParticularsDec 2024Dec 2023
Revenue2,0131,996
Revenue growth+0.9%-
Other income116317
Total expenses1,5601,508
Employee cost240281
EBITDA453488
EBITDA margin+22.5%+24.4%
Depreciation36.7036.50
Interest1.501.70
Profit before tax531767
Tax118164
Net profit442589
Net profit margin+22.0%+29.5%
EPS (₹)179.70262.13
ParticularsDec 2024Dec 2023
Growth
Sales growth+0.9%-
EBITDA growth-7.1%-
PBT growth-30.8%+9997.0%
Net income growth-24.9%-
Profitability & leverage
Net income margin+20.5%+30.2%
Return on capital employed+48.0%+48.1%
Return on net worth+47.1%+58.0%
Debt / equity0.020.02
Long-term debt / equity0.010.01
Interest cover0.360.38
Efficiency & per share
Fixed asset turnover3.653.67
Inventory turnover3.463.01
Debtors turnover11.1315.16
EPS (₹)179.70262.13
Dividend per share (₹)117.00167.00
Book value per share (₹)374.17441.39
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue438472420475406536515524
Revenue growth (YoY)+7.7%-11.9%-18.5%-9.3%-12.3%---
Other income6.204.402.804.908.703.3013.902.30
Total expenses322330330368311364397404
EBITDA11514390.3010794.90172118120
EBITDA margin+26.3%+30.2%+21.5%+22.5%+23.4%+32.1%+23.0%+22.8%
Depreciation8.909.009.509.109.109.609.609.00
Interest0.300.300.600.400.400.300.400.40
Profit before tax11213883.0010294.10165122113
Tax28.8035.3021.3026.3024.6045.8030.9030.40
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue1,8372,0132,8512,7702,9572,9023,071
Revenue growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
Other income19.7011683.1020456489.8094.10
Total expenses1,3731,5602,0472,0662,1942,2302,465
Employee cost185240371406434461450
EBITDA464453804704762671606
EBITDA margin+25.3%+22.5%+28.2%+25.4%+25.8%+23.1%+19.7%
Depreciation37.3036.7039.6041.9066.7082.2099.90
Interest1.701.501.701.701.801.800.30
Profit before tax4455318468641,258677600
Tax118118243244313200186
Net profit346442591526581508452
Net profit margin+18.9%+22.0%+20.7%+19.0%+19.7%+17.5%+14.7%
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
ParticularsDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Growth
Sales growth-8.7%-29.4%+2.9%-6.3%+1.9%-5.5%-
EBITDA growth+2.4%-43.6%+14.1%-7.6%+13.6%+10.8%-
PBT growth-16.3%-37.2%-2.1%-31.3%+85.7%+12.9%-1.6%
Net income growth-21.7%-25.1%+12.3%-9.5%+14.3%+12.4%-
Revenue CAGR (3Y)-12.8%-12.0%-0.6%-3.4%+2.2%+5.7%+9.1%
EBITDA CAGR (3Y)-13.0%-15.9%+6.2%+5.1%+6.9%+7.7%+4.2%
Profitability & leverage
Net income margin+17.8%+20.5%+21.2%+22.4%+31.9%+16.5%+13.5%
Return on capital employed+54.2%+48.4%+70.6%+40.3%+33.8%+28.9%+27.8%
Return on net worth+40.6%+47.2%+52.7%+30.1%+26.8%+20.9%+19.4%
Debt / equity0.020.020.020.010.010.000.00
Long-term debt / equity0.020.010.010.010.010.000.00
Interest cover0.400.360.220.260.260.310.06
Efficiency & per share
Fixed asset turnover3.233.655.315.144.233.483.28
Inventory turnover4.533.465.326.927.786.936.45
Debtors turnover9.0411.1321.8620.3720.3315.6016.06
EPS (₹)142.04179.78262.26269.83410.61207.65180.09
Dividend per share (₹)123.00117.00167.00570.00490.00365.00349.00
Book value per share (₹)325.74374.17441.52554.70967.65921.301,061.87

To see the full year-wise statements and ratios of Sanofi India Limited, buy the company report.

Board of directors of Sanofi India Limited

Sanofi India has 9 current directors and 44 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Vaibhav Vinayak KarandikarDirector23 Feb 20215 Years 8 MonthsCurrent
Rahul Bhatnagar
Also directs: Rossell India Limited, Tasty Bite Eatables Ltd, Whirlpool of India Limited and 1 more
Director29 Jul 20206 Years 2 MonthsCurrent
Deepak AroraManaging Director27 Oct 20250 Years 11 MonthsCurrent
Mahadev Keshav GawadeWhole-Time Director11 Aug 20251 Years 2 MonthsCurrent
Eric Yves MansionDirector03 Jun 20242 Years 4 MonthsCurrent
Rachid Ayari
Also directs: Apollo Sugar Clinics Limited
Whole-Time Director01 Dec 20232 Years 10 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Auditor

Sanofi India Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Price Waterhouse & Co Chartered Accountants LLPFY 2023304026E/E-300009

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 60.40%, foreign institutional investors hold 5.70%, domestic institutional investors hold 19.90% and retail and other public shareholders hold 14.00%.

Promoters: 60.40%DII (Domestic Institutional): 19.90%FII (Foreign Institutional): 5.70%Retail & Others: 14.00%
Sep 2026
QUARTER
60.40% Promoters
19.90% DII (Domestic Institutional)
5.70% FII (Foreign Institutional)
14.00% Retail & Others
Promoter holding - history
Now 60.40% · Sep 2026High 60.40% · Dec 2025Low 60.40% · Dec 2025
59%59.8%60.5%61.3%62%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 60.40%Mar 2026: 60.40%Jun 2026: 60.40%Sep 2026: 60.40%60.40%60.40%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters60.40%60.40%60.40%60.40%
Public39.60%39.60%39.60%39.60%

Charges & borrowings

Open charges
₹170.72 Cr
Satisfied charges
₹40.81 Cr
Breakdown by lending institutions
State Bank of India₹111.60 Cr
Icici Limited₹25.00 Cr
Hdfc Limited₹21.75 Cr
The First National City₹3.20 Cr
Unit Trust of India₹2.00 Cr
Others₹7.17 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
20 Sep 200190229711Hdfc Limited₹19.75 CrOpen
25 Oct 199390228690Icici Limited₹5 CrOpen
31 Dec 199290228611State Bank of India₹40 CrOpen
03 Dec 199290228604State Bank of India₹40 CrOpen
11 Sep 199290228576State Bank of India₹3.2 CrOpen

To see the full charge records of Sanofi India Limited, buy the company report.

Total charge records: 41 View all charges

Deals & funding

Sanofi India Limited has 15 deals on record (12 market trades, 3 acquisitions); the latest was in June 2026.

Total deals
15
Market trades
12
Acquisitions
3

Deals on record (5 of 15)

WhenDealAmountParties
Jun 2026Market trade₹86.63 CrBuyer: Nippon India Mutual Fund
Seller: HDFC Life Insurance Company Limited
Jun 2023Acquisition₹234 CrBuyer: Corona Remedies Limited
Seller: Sanofi India Limited
Jul 2021Acquisition₹587 CrBuyer: Universal Nutriscience Private Limited
Seller: Sanofi India Limited
Mar 2010Acquisition₹416.14 CrBuyer: Sanofi-Aventis SA
Seller: United Breweries (Holdings) Limited
Dec 2007Market trade₹24.9 CrBuyer: Nippon Life India Trustee Limited
Seller: Morgan St Growth Fund

To see the full deal history of Sanofi India Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Sanofi India Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 365 overdue payments to 80 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 80)

SupplierAmount dueDue sinceReported on
Divyashree Packaging Industry
Insignia Communications Private Limited
Dap E-Nnovative Solutions Private Limited
Shah Chemical Corporation
Ample Events & Exhibitions Private Limited

To see the full MSME payment records of Sanofi India Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Sanofi India has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Sanofi Consumer Healthcare India LimitedU21002MH2023PLC402652

To see the full group structure of Sanofi India Limited, buy the company report.

Employees & EPFO

Sanofi India Limited has a workforce of 2,191 employees on its EPFO records as of Jul 30, 2024, across 2 active EPFO establishments.

Employee count
2,191
Active EPFO establishments
2
Employee growth
-8.13%

GST

Sanofi India has 25 GST registrations: 17 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
25
Active
17
Cancelled / inactive
8
GSTINStateStatusRegistered on
27AAACH2736F1ZUMaharashtraActive01 Jul 2017
27AAACH2736F2ZTMaharashtraActive21 Feb 2024
03AAACH2736F1Z4PunjabActive01 Jul 2017
04AAACH2736F1Z2ChandigarhActive01 Jul 2017

To see the full GST registrations and return filing status of Sanofi India Limited, buy the company report.

Recent activity

Sanofi India Limited has 86 board changes on record since 1982: 49 appointments and 37 cessations. The latest: Rajani Kesari was appointed as Director on 01 Apr 2026.

AGM
Sanofi India Limited last Annual general meeting of members was held on 29 Apr 2026 as per latest MCA records.
Appointed
Rajani Kesari was appointed as Director.
Appointed
Siraj Azmat Chaudhry was appointed as Director.
Appointed
Sudipta Chakraborty was appointed as Whole-Time Director.
Filing
Sanofi India Limited has filed its annual Financial statements for the year ended 31 Dec 2025 with Roc Mumbai I.
Appointed
Deepak Arora was appointed as Managing Director.
Appointed
Mahadev Keshav Gawade was appointed as Whole-Time Director.
Ceased
Renee Viswonath Amonkar ceased to be Whole-Time Director.
Ceased
Radhika Kartik Shah ceased to be Company Secretary.
Appointed
Eric Yves Mansion was appointed as Director.
Ceased
Marc Antoine Lucchini ceased to be Director.
Appointed
Rachid Ayari was appointed as Whole-Time Director.

148 earlier events are in the company report.

News

Sanofi Healthcare India: Buys 3.5 Million Shares, 15.20% Of Sanofi India From Hoechst GmbH Through Block Deal; No Change In Promoter Group Ownership.
07 Oct 2026 · Exchange Update
SANOFI: RS 1068.2CR NSE BLOCK TRADE; FOR ~3500000 SHARES, AT RS 3052 (PRE-OPEN)
24 Sep 2026 · Exchange Update

Frequently asked questions

Sanofi India is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 May 1956 (70+ years old) and is registered under CIN L24239MH1956PLC009794. Listed on BSE: 500674 and NSE: SANOFI.

Sanofi India reported revenue of ₹1,837.4 Cr for FY 2024-25 (down 8.7% YoY) based on standalone financials.

Sanofi India has 9 current directors:

The latest financial statements of Sanofi India on record with the MCA are for the year ended 31 December 2025. Its last annual general meeting was held on 29 April 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Sanofi India is 27AAACH2736F1ZU, registered in Maharashtra. The company has 25 GST registrations in all, of which 17 are active and 8 are cancelled or inactive. Other active GSTINs include 27AAACH2736F2ZT (Maharashtra), 03AAACH2736F1Z4 (Punjab), 04AAACH2736F1Z2 (Chandigarh).

The CIN (Corporate Identification Number) of Sanofi India is L24239MH1956PLC009794. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Sanofi India is a listed company as per MCA records. Its shares are listed on both BSE (code: 500674) and NSE (symbol: SANOFI).

Sanofi India has 454 court cases on record: 197 filed by the company and 259 filed against it. 119 are pending. Most are in the district courts.

Sanofi India was incorporated on 02 May 1956, making it 70+ years old. It is registered with the Registrar of Companies, Mumbai.

Sanofi India has 15 deals on record (12 market trades, 3 acquisitions); the latest was in June 2026.

Rajani Kesari was appointed as Director on 01 Apr 2026. Siraj Azmat Chaudhry was appointed as Director on 01 Apr 2026. Sudipta Chakraborty was appointed as Whole-Time Director on 01 Mar 2026. Sanofi India has 86 board changes on record in total.